Amlodipine Pre-Surgery Hold Window: What Clinicians Need to Know

Why the Hold-Window Question Matters for Amlodipine Specifically

Most antihypertensive classes present a binary perioperative choice: hold and risk rebound, or continue and risk exaggerated hypotension. Amlodipine complicates this because its pharmacokinetics make the binary choice largely irrelevant. A patient who skips their morning dose on the day of surgery still carries near-full plasma concentrations into the operating room.

Understanding this requires separating amlodipine's pharmacology from the class assumptions clinicians often import from older dihydropyridine data.

The Pharmacokinetic Case Against a Short Hold

Amlodipine reaches peak plasma concentration 6 to 12 hours after an oral dose, with a mean elimination half-life of approximately 35 to 50 hours in healthy adults and up to 65 hours in patients with hepatic impairment [1]. At steady state, omitting a single dose reduces plasma concentration by less than 50% over a 24-hour period. A 48-hour hold would reduce concentrations to roughly 25 to 50% of steady-state, but even then, meaningful vasodilatory activity persists.

This is not theoretical. A 2003 pharmacokinetic modeling study confirmed that patients who missed one dose of amlodipine 10 mg still maintained trough concentrations well within the therapeutic range, with a predicted drop of only 28 to 34% at 24 hours [2].

Clinically, this means the standard "hold the night before" instruction has essentially no hemodynamic effect. The drug is still there.

Contrast With Shorter-Acting Calcium Channel Blockers

Immediate-release nifedipine (half-life 2 to 5 hours) and diltiazem (half-life 3 to 5 hours) behave very differently perioperatively. Holding them 12 to 24 hours before surgery does meaningfully lower plasma levels, and abrupt withdrawal can trigger reflex tachycardia or angina in susceptible patients. Clinicians should not apply nifedipine or diltiazem hold logic to amlodipine.

Current Guideline Recommendations on Perioperative Calcium Channel Blockers

The 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery provides the most widely used framework for this decision. The guideline states: "Continuation of beta-blockers is recommended for patients currently taking beta-blockers... Calcium-channel blockers used for the management of hypertension may be continued perioperatively" [3].

That phrasing, "may be continued," carries a Class IIb recommendation (Level of Evidence: B). It is permissive, not mandatory, but no guideline currently recommends routine pre-surgical discontinuation of long-acting calcium channel blockers like amlodipine.

What the ESC Says

The 2022 ESC Guidelines on Cardiovascular Assessment and Management of Patients Undergoing Non-Cardiac Surgery reinforce this position. The document notes that antihypertensive therapy, including calcium channel blockers, should generally be maintained perioperatively to avoid hypertensive crises and cardiovascular complications [4]. The ESC does flag that ACE inhibitors and ARBs present more complex decisions (and recommends withholding them on the day of surgery in many cases), but long-acting dihydropyridines are not placed in that problematic category.

The ASCOT-BPLA Context

The ASCOT-BPLA trial (N=19,257) randomized hypertensive patients to an amlodipine-based regimen (amlodipine 5 to 10 mg plus perindopril as needed) versus an atenolol-based regimen over a median follow-up of 5.5 years. The trial was stopped early because the amlodipine arm showed a 10% reduction in all-cause mortality (P=0.0247) and a 23% reduction in fatal and nonfatal stroke (P<0.0001) compared with atenolol-based therapy [5].

ASCOT-BPLA is not a perioperative trial. But it established that sustained, uninterrupted amlodipine therapy produces durable cardiovascular benefit, which is exactly the kind of evidence that supports minimizing unnecessary interruptions to treatment.

Hemodynamic Risks of Continuing Amlodipine Into Surgery

Continuing amlodipine is generally the right call, but it is not without risk. The drug's vasodilatory mechanism can synergize with volatile anesthetic agents to produce exaggerated intraoperative hypotension.

Mechanism of Interaction With Volatile Anesthetics

Volatile anesthetics (sevoflurane, isoflurane, desflurane) depress myocardial contractility and reduce systemic vascular resistance through direct effects on voltage-gated L-type calcium channels, the same channels amlodipine blocks peripherally [6]. The combination can produce greater reductions in mean arterial pressure than either agent alone.

A prospective observational study published in Anesthesia and Analgesia found that patients on calcium channel blockers required vasopressor support approximately 30% more frequently during major abdominal surgery compared to matched controls not on antihypertensives [7]. The hypotension was typically responsive to treatment and did not prolong hospital stay in that cohort.

Neuraxial Blocks Add Further Risk

Spinal and epidural anesthesia reduce sympathetic tone, dropping both preload and afterload. In a patient whose peripheral vasculature is already partially blocked by amlodipine, neuraxial techniques carry a higher likelihood of clinically significant hypotension. Pre-loading with 500 to 1,000 mL of crystalloid before neuraxial block placement is standard practice, but anesthesiologists should specifically note preoperative amlodipine use when planning vasopressor dosing.

Vasopressor Choice When Amlodipine Is On Board

Phenylephrine (a pure alpha-1 agonist) is generally preferred for first-line treatment of intraoperative hypotension in patients on dihydropyridine CCBs. Ephedrine's mixed alpha/beta activity may be less reliable because beta-mediated vasodilation compounds existing calcium-channel-mediated vasodilation. Vasopressin (0.03 to 0.04 units/minute) is another option for refractory hypotension, acting via V1 receptors entirely independent of the L-type calcium channel pathway [8].

Patient-Specific Factors That Change the Decision

The "continue amlodipine" default applies to most elective surgical patients with well-controlled hypertension. Several clinical scenarios call for a more individualized assessment.

Patients With Baseline Hypotension or Low Cardiac Reserve

A patient whose resting systolic blood pressure runs 100 to 110 mmHg on amlodipine 10 mg is at genuine risk of profound intraoperative hypotension. In these cases, the prescribing physician and anesthesiologist should discuss whether a dose reduction (for example, dropping from 10 mg to 5 mg three to five days before surgery) achieves a safer baseline while preserving much of the antihypertensive effect.

Abrupt full discontinuation still makes pharmacokinetic sense only if started at least four to five half-lives before surgery, meaning roughly seven to ten days for most patients. This is rarely practical in elective scheduling, and rebound hypertension, while less severe than with beta-blockers, has been reported with sudden withdrawal of amlodipine after long-term use [9].

Patients With Vasospastic Angina (Prinzmetal's)

Amlodipine is the preferred agent for vasospastic angina. Stopping it perioperatively in these patients risks coronary vasospasm, particularly during the sympathetic surge of laryngoscopy or surgical stress. The 2014 ACC/AHA guideline places coronary vasospasm management squarely in the "continue" column regardless of surgical setting [3].

Hepatic Impairment

The FDA label for amlodipine specifies that patients with severe hepatic impairment can have half-lives exceeding 65 hours [1]. This further diminishes any hemodynamic benefit from a short hold while increasing the duration of residual drug activity postoperatively. Dose reduction (2.5 mg once daily) is the appropriate perioperative adjustment in this population, not discontinuation.

Pediatric and Geriatric Considerations

In patients older than 65, amlodipine clearance declines modestly (mean half-life approximately 65 hours vs. 35 to 50 hours in younger adults). Geriatric patients also have reduced baroreceptor sensitivity, making them more susceptible to position-dependent hypotension when amlodipine is combined with general or neuraxial anesthesia. The anesthesia team should be explicitly informed when a geriatric patient is taking amlodipine, regardless of the decision to continue or hold.

The HealthRX Perioperative Amlodipine Decision Framework (reviewed by the HealthRX medical team) organizes this as three branches:

1. Elective surgery, controlled BP, normal hepatic function: Continue amlodipine at current dose through the morning of surgery with a small sip of water.
2. Elective surgery, baseline SBP <105 mmHg or severe hepatic impairment: Discuss dose reduction to 2.5 to 5 mg starting five to seven days before surgery; do not hold outright without PK-guided timing.
3. Emergency surgery or vasospastic angina: Continue amlodipine; alert anesthesia team for proactive vasopressor planning.

Perioperative Monitoring and Anesthetic Planning

Effective perioperative management of a patient on amlodipine goes beyond a single hold-or-continue decision.

Pre-Anesthesia Checklist Items

The anesthesiology team should document: current amlodipine dose and duration of use, last dose time, baseline blood pressure range over the prior two weeks (not just the day-of reading), hepatic function status, and any concurrent antihypertensives. A patient on amlodipine 10 mg plus an ARB plus a diuretic carries a very different hemodynamic profile than one on amlodipine 5 mg monotherapy.

Intra-arterial blood pressure monitoring is worth considering for major procedures in patients on high-dose amlodipine, since beat-to-beat data allows faster vasopressor titration than oscillometric cuffs at five-minute intervals.

Postoperative Resumption

Resume amlodipine as soon as the patient tolerates oral intake. The drug's long half-life means that a 12-to-24-hour gap after surgery does not create a clinical void, but delaying resumption beyond 48 hours risks genuine trough effect, especially if systemic inflammation and the post-surgical stress response are also elevating blood pressure.

IV alternatives are limited: amlodipine has no intravenous formulation. Nicardipine IV (a shorter-acting dihydropyridine) can bridge the gap if oral intake is delayed and blood pressure control is urgent, typically dosed at 5 to 15 mg/hour titrated to effect [10].

Amlodipine's Cardiovascular Evidence Base: Why Interrupting Therapy Carries Long-Term Risk

The perioperative window is short, but the cardiovascular literature makes clear that consistent amlodipine therapy reduces long-term event rates in ways that matter when cumulating treatment gaps.

CAMELOT and Coronary Atherosclerosis

The CAMELOT trial (N=1,991) randomized patients with coronary artery disease and normal blood pressure to amlodipine 10 mg, enalapril 20 mg, or placebo for 24 months. The amlodipine arm showed a 31% reduction in adverse cardiovascular events compared with placebo (P=0.003) and, in the NORMALISE substudy using intravascular ultrasound, demonstrated statistically significant slowing of coronary atherosclerosis progression [11].

These effects accrue over months and years of uninterrupted exposure. A single perioperative hold does not erase them. The data do argue, however, that clinicians and surgical teams should treat a hold as a deliberate medical decision with documentation, not a default checkbox.

PREVENT Trial: Subclinical Atherosclerosis

PREVENT (N=825) showed that amlodipine 10 mg slowed carotid intima-media thickness progression over three years compared with placebo (P<0.02) in patients with coronary artery disease [12]. Again, this is chronic-therapy data, but it contextualizes why a gratuitous perioperative hold in a high-risk cardiovascular patient is not trivially safe.

ACC/AHA Hypertension Guideline Target Context

The 2017 ACC/AHA Hypertension Guideline defines stage 1 hypertension as systolic BP 130 to 139 mmHg or diastolic BP 80 to 89 mmHg and recommends drug therapy for patients with 10-year ASCVD risk of 10% or higher [13]. Amlodipine is one of four preferred first-line drug classes (alongside ACE inhibitors/ARBs and thiazides) in this guideline. Patients on amlodipine for guideline-indicated indications generally should not have that therapy interrupted for the convenience of surgical scheduling.

Special Procedure Considerations

Cardiac Catheterization

Diagnostic cardiac catheterization or percutaneous coronary intervention does not require holding amlodipine. Contrast administration is the primary nephroprotection concern, not calcium channel blockade. Amlodipine may in fact be mildly renoprotective via afferent arteriolar vasodilation, though this is not an established indication [14].

Neuraxial Procedures (Epidural Steroid Injections, Spinal Cord Stimulator Trials)

For interventional pain procedures performed under moderate sedation or local anesthesia only, the hemodynamic perturbation is much smaller than for general anesthesia. Continuing amlodipine through these procedures is generally appropriate. The relevant risk is positional hypotension during prone positioning in the procedural suite; nursing staff should be prepared to assist with position changes slowly.

Outpatient Endoscopy

Upper and lower endoscopy under propofol sedation rarely produces significant hypotension in otherwise healthy patients. Amlodipine should be continued without modification for routine endoscopic procedures.

Drug Interactions Relevant to the Perioperative Period

Several agents commonly used in the perioperative period interact with amlodipine through CYP3A4.

Diltiazem and verapamil, sometimes administered for rate control in postoperative atrial fibrillation, inhibit CYP3A4 and can raise amlodipine plasma concentrations by 50 to 60% when co-administered [1]. If rate control with a non-dihydropyridine CCB is needed postoperatively in a patient already on amlodipine, the anesthesiologist and cardiologist should flag this interaction explicitly.

Fluconazole and itraconazole (CYP3A4 inhibitors used in surgical prophylaxis for certain immunocompromised patients) similarly raise amlodipine exposure. Dose adjustment of amlodipine may be warranted if these agents are needed for more than 48 hours postoperatively.

Strong CYP3A4 inducers such as rifampin, if used perioperatively for mycobacterial coverage, can reduce amlodipine plasma levels by up to 60% within days, potentially undermining blood pressure control during recovery [1].